MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Early detection of ovarian cancer

Back to overy Blogs list Cancer blog  


Subscribe To Overy RSS Feed  RSS content feed What is RSS feed?

Early detection of ovarian cancer




Despite a number of research advances, ovary cancer remains lethal in a majority of cases, due to late diagnosis of the disease. In a newly released study, Dr. Joshua LaBaer of the Biodesign Institute at Arizona State University, along with Arturo Ramirez and Paul Lampe, scientists at the Fred Hutchinson Cancer Research Center in Seattle, used a novel method for identifying biomarkers-proteins in blood that can identify ovary cancer before symptoms appear.

The work, which appeared recently in the journal Molecular and Cellular Proteomics, holds the potential for significant improvements in patient survival rate. The research is part of the Early Detection Research Network program of the National Cancer Institute.



Early detection of ovarian cancer
Joshua LaBaer

As LaBaer notes, ovary cancer is an attractive target for biomarker study. "This is a disease for which an early diagnostic test would make an enormous difference in the health of women." Highly treatable in its early stage, ovary cancer is typically not identified until it has progressed to stage 3 or beyond. Often, it is detected accidentally, in the course of some other test or procedure, for example, during an oophorectomy. "By the time it's caught," LaBaer says, "it has commonly speckled the abdomen with advanced tumors".

At present, only one reliable biomarker for ovary cancer exists. Known as CA 125, this protein is produced on the surface of cells and released into the bloodstream. Elevated levels of CA 125 are indicative of ovary cancer, but testing for CA 125 alone is not adequate. Such tests can produce both false positive and false negative results. Further, the level of CA 125 tends to go up in proportion to tumor growth, sometimes providing good evidence only after the disease has reached its later, terminal stages.

LaBaer stresses that reliable early detection will require the discovery and combined application of multiple biomarkers. One innovative way to hunt for them involves the use of antibodies. These proteins-produced by the B cells of the body's immune system-are able to selectively bind with disease-associated antigens. Various techniques permit scientists to probe blood serum, pulling out the antigens that bind to the antibodies and observing them with the aid of fluorescence or other methods.

Traditional means of producing antibodies for research are labor-intensive and cumbersome, requiring injection of antigens into animals, which then act as production sites for the antibodies of interest. A new method however allows antibodies to be engineered synthetically. In this scenario, the portion of the antibody responsible for binding with an antigen, known as the variable region, is built from amino acids. These single chain variable fragments or scFvs can be inserted into bacteria, which act as vectors for the antibody fragments, much as a mouse or other animal would carry a traditional antibody.

scFvs encoded in bacteria have been assembled into vast libraries, capable of probing the full complexity of proteins found in blood. When an scFv detects something unusual in the blood that may suggest an abnormality, it binds to it, just as in a normal immune response. Ramirez used a library of scFvs to find which antibody fragments selectively attached to proteins in blood carrying ovary cancer, eliminating the antibodies that bound with proteins in normal blood. The method yielded 19 distinct scFvs that appeared to display specific affinity for proteins exclusively found in ovarian malignant blood serum.

Identification of the protein antigens bound to these scFvs however, proved far trickier. After several years of frustrating attempts to recognize these protein culprits, Ramirez teamed up with LaBaer, applying a new method that would allow them to screen the cancer-associated scFvs against thousands of proteins of known sequence.

The technique-known as NAPPA (for nucleic acid programmable protein array), provides a convenient means to display thousands of different proteins. Further, proteins used in NAPPA are synthesized freshly for each experiment and do not require the lengthy processes of purification necessary with conventional protein arrays.

When the team screened the 19 selected ScFvs, they observed that about two thirds stuck to a target in the NAPPA array, allowing for positive identification. Intriguingly, these distinct ScFvs bound with the same protein, evidentially attaching to different regions. As LaBaer notes, this fact offers tantalizing hints that the technique may indeed have sniffed out a consistent biomarker for ovary cancer, rather than anomalous proteins lacking true predictive power.

The study also examined proximal tumor fluid for ovary cancer, detecting in high concentrations the key protein antigens identified with the microarray. As per LaBaer, this finding provides further support for the idea that these proteins are indeed linked to ovary cancer, and do not represent mere anomalies.


Posted by: Emily    Source




Did you know?
Despite a number of research advances, ovary cancer remains lethal in a majority of cases, due to late diagnosis of the disease. In a newly released study, Dr. Joshua LaBaer of the Biodesign Institute at Arizona State University, along with Arturo Ramirez and Paul Lampe, scientists at the Fred Hutchinson Cancer Research Center in Seattle, used a novel method for identifying biomarkers-proteins in blood that can identify ovary cancer before symptoms appear.

Medicineworld.org: Early detection of ovarian cancer

Ectopic pregnancy| Hyperemesis gravidarum vomiting of pregnancy| Obgyn| Menopause symptoms| Pre eclampsia| Seizures in pregnancy| Spontaneous abortion miscarriage| Symptoms of pregnancy| Ovariancancer| Ovarian cancer statistics| Risk factors for ovarian cancer| Role of radiation therapy in the treatment of ovarian cancer| Role of screening in ovarian cancer| Staging of ovarian cancer| Symptoms of ovarian cancer| Treatment of advanced stage ovarian cancer| Treatment of early stage ovarian cancer| Treatment of ovarian cancer| Treatment of recurrent ovarian cancer| What causes ovarian cancer| Who is more prone to ovarian cancer|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.